Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: Macrophage interleukin (IL)-10 signalling plays a critical role in the maintenance of a regulatory phenotype that prevents the development of IBD. We have previously found that anti-tumour necrosis factor (TNF) monoclonal antibodies act through Fcγ-receptor (FcγR) signalling to promote repolarisation of proinflammatory intestinal macrophages to a CD206+ regulatory phenotype. The role of IL-10 in anti-TNF-induced macrophage repolarisation has not been examined. Design: We used human peripheral blood monocytes and mouse bone marrow-derived macrophages to study IL-10 production and CD206+ regulatory macrophage differentiation. To determine whether the efficacy of anti-TNF was dependent on IL-10 signalling in vivo and in which cell type, we used the CD4+CD45Rb high T-cell transfer model in combination with several genetic mouse models. Results: Anti-TNF therapy increased macrophage IL-10 production in an FcγR-dependent manner, which caused differentiation of macrophages to a more regulatory CD206+ phenotype in vitro. Pharmacological blockade of IL-10 signalling prevented the induction of these CD206+ regulatory macrophages and diminished the therapeutic efficacy of anti-TNF therapy in the CD4+CD45Rb high T-cell transfer model of IBD. Using cell type-specific IL-10 receptor mutant mice, we found that IL-10 signalling in macrophages but not T cells was critical for the induction of CD206+ regulatory macrophages and therapeutic response to anti-TNF. Conclusion: The therapeutic efficacy of anti-TNF in resolving intestinal inflammation is critically dependent on IL-10 signalling in macrophages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lucas, M., Zhang, X., Prasanna, V., & Mosser, D. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.1.469 · Cited by 197
Cited by
Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review
Zhao, M., Chu, J., Feng, S., Guo, C., Xue, B., He, K., & Li, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114985 · Cited by 458
Strategies for targeting cytokines in inflammatory bowel disease
Neurath, M. F. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01008-6 · Cited by 398
Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review
Al-Qahtani, A. A., Alhamlan, F. S., & Al-Qahtani, A. A. (2024) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed9010013 · Cited by 291
Metadata
- Authors
- Koelink, P. J., Bloemendaal, F. M., Li, B., Westera, L., Vogels, E. W. M., van Roest, M., Gloudemans, A. K., van 't Wout, A. B., Korf, H., Vermeire, S., te Velde, A. A., Ponsioen, C. Y., D'Haens, G. R., Verbeek, J. S., Geiger, T. L., Wildenberg, M. E., & van den Brink, G. R.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2019-09-10
- Volume
- 69
- Issue
- 6
- Pages
- 1053-1063
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2972957964
- Cited by
- 227
- References
- 1
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. https://app.cochat.ai/papers/10.1136/gutjnl-2019-318264
- The paper
- Koelink, P. J., Bloemendaal, F. M., Li, B., Westera, L., Vogels, E. W. M., van Roest, M., Gloudemans, A. K., van 't Wout, A. B., Korf, H., Vermeire, S., te Velde, A. A., Ponsioen, C. Y., D'Haens, G. R., Verbeek, J. S., Geiger, T. L., Wildenberg, M. E., & van den Brink, G. R. (2020). Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut. https://doi.org/10.1136/gutjnl-2019-318264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.